Floatz logo

Fluciclatide

Sarcoma

GE Healthcareprotein_peptidePhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Inno-206
City of Hope Medical Center
Phase 3BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Fluciclatide is also rated in:

malignant gliomaDormant
CCC
Indicative ·
50 / 100
View asset →
head and neck cancerDormant
CCC
Indicative ·
50 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →